Trial reportLasers in medical science2026
Transurethral anatomical enucleation of the prostate using a 1470-nm diode laser (DiLEP) versus transurethral resection of the prostate (TURP) for large-volume benign prostatic hyperplasia: a prospective randomized controlled trial.
Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the efficacy of transurethral anatomical enucleation using a 1470-nm diode laser (DiLEP) (1470 nm DiLEP) versus transurethral resection of the prostate (TURP) in improving lower urinary tract symptoms (LUTS) in patients with large-volume benign prostatic obstruction (BPO). In this prospective, open-label, randomized controlled trial, a total of 121 patients with large-volume BPO (> 90 ml) who visited xx Hospital between June 2022 and December 2023 were enrolled. Patients were randomly assigned using a random number table to the 1470 nm DiLEP group (n = 61) or the TURP group (n = 60). Perioperative variables, as well as functional outcomes and complications at 6 and 12 months postoperatively, were compared between the two groups. No statistically significant differences existed between groups at baseline for age, prostate volume, maximum urinary flow rate (Qmax), residual urine volume, International Prostate Symptom Score (IPSS), or quality of life (QoL) scores (P > 0.05). The 1470 nm DiLEP group demonstrated significantly shorter operative time, smaller hemoglobin decrease, lower sodium decrease, shorter catheterization duration, and shorter hospitalization compared to the TURP group (P < 0.05); There were no statistically significant differences between the two groups in Qmax, residual urine volume, IPSS, QoL, Transient stress urinary incontinence (SUI), or bladder neck contracture at 6 and 12 months postoperatively (P > 0.05). However, the incidence of retrograde ejaculation at 6 and 12 months postoperatively was significantly lower in the 1470 nm DiLEP group compared to the TURP group, while IIEF-5 scores were markedly improved (P < 0.05). 1470 nm DiLEP and TURP demonstrate comparable efficacy in patients with large-volume BPO. However, 1470 nm DiLEP offers superior safety, faster postoperative recovery, and minimal impact on sexual function. It is therefore more suitable for patients with large-volume BPO who maintain certain expectations for postoperative sexual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.